Viatris Inc. (VTRS)
NASDAQ: VTRS · IEX Real-Time Price · USD
11.57
-0.21 (-1.78%)
At close: Apr 30, 2024, 4:00 PM
11.41
-0.16 (-1.38%)
After-hours: Apr 30, 2024, 6:15 PM EDT
Viatris Revenue
In the year 2023, Viatris had annual revenue of $15.43B, a decrease of -5.14%. Revenue in the quarter ending December 31, 2023 was $3.84B, a -1.00% decrease year-over-year.
Revenue (ttm)
$15.43B
Revenue Growth
-5.14%
P/S Ratio
0.89
Revenue / Employee
$405,971
Employees
38,000
Market Cap
13.74B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 15.43B | -835.80M | -5.14% |
Dec 31, 2022 | 16.26B | -1.62B | -9.08% |
Dec 31, 2021 | 17.89B | 5.94B | 49.73% |
Dec 31, 2020 | 11.95B | 445.50M | 3.87% |
Dec 31, 2019 | 11.50B | 66.60M | 0.58% |
Dec 31, 2018 | 11.43B | -473.80M | -3.98% |
Dec 31, 2017 | 11.91B | 830.80M | 7.50% |
Dec 31, 2016 | 11.08B | 1.65B | 17.47% |
Dec 31, 2015 | 9.43B | 1.71B | 22.15% |
Dec 31, 2014 | 7.72B | 810.50M | 11.73% |
Dec 31, 2013 | 6.91B | 113.00M | 1.66% |
Dec 31, 2012 | 6.80B | 666.28M | 10.87% |
Dec 31, 2011 | 6.13B | 679.30M | 12.46% |
Dec 31, 2010 | 5.45B | 357.74M | 7.02% |
Dec 31, 2009 | 5.09B | -44.80M | -0.87% |
Dec 31, 2008 | 5.14B | 3.53B | 218.74% |
Mar 31, 2007 | 1.61B | 354.66M | 28.21% |
Mar 31, 2006 | 1.26B | 3.79M | 0.30% |
Mar 31, 2005 | 1.25B | -121.24M | -8.82% |
Mar 31, 2004 | 1.37B | 105.43M | 8.31% |
Mar 31, 2003 | 1.27B | 165.14M | 14.96% |
Mar 31, 2002 | 1.10B | 257.35M | 30.40% |
Mar 31, 2001 | 846.70M | 56.55M | 7.16% |
Mar 31, 2000 | 790.15M | 69.02M | 9.57% |
Mar 31, 1999 | 721.12M | 165.70M | 29.83% |
Mar 31, 1998 | 555.42M | 115.23M | 26.18% |
Mar 31, 1997 | 440.19M | 47.33M | 12.05% |
Mar 31, 1996 | 392.86M | -3.26M | -0.82% |
Mar 31, 1995 | 396.12M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Walgreens Boots Alliance | 144.60B |
Teva Pharmaceutical | 15.85B |
Quest Diagnostics | 9.29B |
Revvity | 2.75B |
BioMarin Pharmaceutical | 2.47B |
BeiGene | 2.46B |
Royalty Pharma | 2.35B |
Neurocrine Biosciences | 1.89B |
VTRS News
- 14 days ago - Viatris to Report First Quarter 2024 Financial Results on May 9, 2024 - PRNewsWire
- 15 days ago - Viatris Appoints Corinne Le Goff as Chief Commercial Officer - PRNewsWire
- 26 days ago - UK watchdog says Theramex-Viatris deal raises competition concerns - Reuters
- 4 weeks ago - Teva, Viatris win new chance to challenge J&J schizophrenia drug patent - Reuters
- 4 weeks ago - Viatris Announces the Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% in the United States - PRNewsWire
- 4 weeks ago - Viatris Hosts R&D Event Focusing on its Collaboration with Idorsia, Phase 3 Assets Selatogrel and Cenerimod and Key Elements of its Pipeline - PRNewsWire
- 6 weeks ago - Idorsia and Viatris successfully close the transaction for the global research and development collaboration - GlobeNewsWire
- 7 weeks ago - Scott+Scott Attorneys at Law LLP & Hedin Hall LLP Announce Notice of Class Action and Proposed Settlement to All Who Purchased or Acquired Shares of Viatris Inc. Pursuant to a November 2020 Merger of Mylan N.V. and Upjohn, Inc. to Form Viatris - PRNewsWire